Skip to main content

Table 3 Relationships between clinicopathological criteria, cytoplasmic IGFBP-3 and patient outcome

From: Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

Variable Univariate analysis Multivariate analysis
  95% CI P 95% CI P
Overall survival     
   Age 0.99–1.04 0.4 0.98–2.90 0.009
   Lymph node status (+/-) 2.79–153.9 0.004 2.65–161 0.003
   Invasive tumour grade (I, II, III) 1.27–4.93 0.002 1.14–4.62 0.002
   Tumour size 1.02–1.05 <0.001 1.02–1.05 <0.001
   NPI 1.48–3.36 <0.001 1.39–3.32 <0.001
   ER (quick-score) 0.66–0.92 0.002 0.68–0.98 0.03
   HER-2 IHC score 0.94–2.02 0.04 0.76–1.95 0.56
   Ki67 proliferative index 0.99–1.00 0.4 0.99–1.00 0.65
   Lymphovascular invasion (+/-) 1.46–9.38 0.006 0.89–6.69 0.08
   IGFBP-3 IHC score 0.62–2.01 0.719 0.59–2.50 0.592
Disease-free survival     
   Age 0.97–1.02 0.9 0.99–1.06 0.06
   Lymph node status (+/-) 2.29–25.3 <0.001 2.06–25.6 0.002
   Invasive tumour grade (I, II, III) 1.48–5.38 0.005 1.36–5.11 0.006
   Tumour size 1.02–1.04 <0.001 1.02–1.04 <0.001
   NPI 1.46–3.17 <0.001 1.38–3.15 <0.001
   ER (quick-score) 0.66–0.89 0.001 0.68–0.95 0.01
   HER-2 IHC score 1.04–1.92 0.02 0.95–1.87 0.2
   Ki67 proliferative index 0.99–1.00 0.2 0.99–1.00 0.3
   Lymphovascular invasion (+/-) 1.63–6.95 0.002 1.09–6.65 0.03
   IGFBP-3 IHC score 0.61–1.71 0.922 0.57–1.90 0.896
  1. Confidence intervals (CI) and P values are given for the results of both the univariate and multivariate analyses. The multivariate analysis is adjusted for Nottingham Prognostic Index (NPI) (nodes, grade and size) and treatment (tamoxifen/chemotherapy/none). Data for univariate analysis were evaluable in 95 patients (reflecting the exclusion of six local tumour recurrences as described in the Methods section) and included a multivariate analysis on 84 cases that excluded non-evaluable NPI in 11 patients. All clinicopathological variables and cytoplasmic IGFBP-3 immunohistochemistry (IHC) scores were analysed as a continuum, with lymph node status and lymphovascular invasion assessed as present or absent. Significant P values (P < 0.05) are indicated in bold.
  2. ER, oestrogen receptor.